<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04308590</url>
  </required_header>
  <id_info>
    <org_study_id>CORT125134-456</org_study_id>
    <nct_id>NCT04308590</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas</brief_title>
  <acronym>GRADIENT</acronym>
  <official_title>Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients With Cortisol-Secreting Adrenal Adenomas or Hyperplasia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corcept Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corcept Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy,
      and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting
      adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance
      and/or uncontrolled systolic hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 3 study patients will be randomized in a 1:1 ratio to treatment with relacorilant
      (active drug) or placebo. Patients will receive relacorilant or placebo for 22 weeks.
      Patients who complete the study may also be eligible to roll over into an extension study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In patients with diabetes/ impaired glucose tolerance (DM/IGT), the mean change in AUC glucose as compared between relacorilant and placebo arm</measure>
    <time_frame>Baseline to week 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In patients with systolic hypertension, the change in mean systolic blood pressure (SBP) based on 24-hour ambulatory blood pressure monitor (ABPM) as compared between relacorilant and placebo arms</measure>
    <time_frame>Baseline to week 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of safety based TEAEs</measure>
    <time_frame>Baseline to week 22</time_frame>
    <description>Assessment of safety based on treatment-emergent adverse events (TEAEs) as graded by CTCAE v5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In patients with DM at baseline the mean change in HbA1c and fasting glucose</measure>
    <time_frame>Baseline to week 22/ET</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with IGT at Baseline who achieved normalization of 2-hour oGTT glucose</measure>
    <time_frame>Week 22/ET</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with normalization of the mean SBP</measure>
    <time_frame>Baseline to week 22/ET</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Hypercortisolism</condition>
  <arm_group>
    <arm_group_label>Relacorilant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of relacorilant will be increased sequentially from 100 mg orally once daily to a target dose of 400 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to study drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>relacorilant</intervention_name>
    <description>Relacorilant is supplied as 100 mg capsules for oral dosing.</description>
    <arm_group_label>Relacorilant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is supplied as 100 mg capsules for oral dosing.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Shows lack of cortisol suppression

          -  Suppressed or low early-morning ACTH levels

          -  A radiologically confirmed adrenal lesion

          -  Has IGT or DM

          -  Has uncontrolled hypertension

        Exclusion Criteria:

          -  Has severe, uncontrolled hypertension

          -  Has poorly controlled DM

          -  Has significantly abnormal liver test results or severe renal insufficiency

          -  Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Moraitis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Corcept Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Lead</last_name>
    <phone>650 327 3270</phone>
    <email>GRADIENTstudy@corcept.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 08</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 06</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 07</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 03</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79935</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 05</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 04</name>
      <address>
        <city>Shavano Park</city>
        <state>Texas</state>
        <zip>78231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cushing syndrome</keyword>
  <keyword>Cushing</keyword>
  <keyword>Hypercortisolemia</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Impaired Glucose Intolerance</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Adrenocorticotropic hormone</keyword>
  <keyword>Primary Pigmented Nodular Adrenal Disease</keyword>
  <keyword>Macronodular adrenal hyperplasia</keyword>
  <keyword>Adrenal Adenoma</keyword>
  <keyword>Adrenal Autonomy</keyword>
  <keyword>Cortisol</keyword>
  <keyword>Autonomous cortisol secretion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Adrenocortical Adenoma</mesh_term>
    <mesh_term>Cushing Syndrome</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

